Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,300 Cr
verified against source
Revenue YoY
17.6%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
EPL delivered a strong Q4 FY26 with revenue growth of 17.6% YoY, the highest in five years, driven by a 30% surge in beauty & cosmetics and a recovery in oral care (up 10%). EBITDA grew 17.2% with margins sustained above 20% for the seventh consecutive quarter. All four regions posted double-digit growth, led by EAP (25%) and Americas (24.1%). The proposed merger with Indova was announced, expected to create a nearly $1B platform. Management guided for continued low double-digit revenue growth (11-13%) and reiterated confidence in passing through raw material cost inflation from the Middle East crisis. Key risk: volatility in raw material availability and cost could pressure near-term margins if pass-through lags.
Colored figures show movement against the previous available record.
Guidance to track
- Long-term low double-digit revenue growth guidance maintained; FY26 full-year growth was 13%.
- Management expects EBITDA growth to outpace revenue growth over the long term.
- Proposed merger with Indova expected to complete in about 12 months from announcement (end of March 2026).
- Investments in beauty & cosmetics capacity and innovation will keep capex above depreciation in FY27.
Risks flagged
- The crisis has affected both availability and cost of key raw materials; management is proactively managing but uncertainty remains.
- Analyst questioned whether non-contractual customers may have a lag in accepting price increases; management claimed no lag but this is unproven.
- High capex (₹480 cr in FY26) and investments in B&C may pressure near-term margins despite revenue growth.
- The merger with Indova requires multiple approvals; timeline may extend beyond Q4 FY27, delaying synergies.
Key quotes
- This is the highest ever revenue growth in the last 5 years. This is also the fourth consecutive quarter of double-digit revenue growth reflecting the consistency and strength of our performance.
- Our strategic shift towards beauty and cosmetics is now translating into results with the segment delivering fourth consecutive quarter of over 20% growth.
- We are confident that we will recover the full cost impact and we do not think that there will be a lag in recovery of the cost.
Research modules